FDA approves Mirum’s drug for ultra-rare soft tissue disease
RegulatoryapprovedAtebriozPositive
AI Analysis
Summary
The FDA has approved Mirum Pharmaceuticals' zilurgisertib (Atebrioz), an ALK2 receptor inhibitor, marking the third approved treatment for a rare genetic disease that causes muscle and connective tissue to ossify. This represents a significant regulatory milestone for the ultra-rare indication.
Outcome Details
FDA approval for third treatment option for rare genetic disease affecting muscle and connective tissue
Importance:9/10
Sentiment:
0.95
FDA approvalrare diseasegenetic disorderALK2 inhibitor
Related Companies
Read the original article
Published by Endpoints News on September 25, 2026 7:46 PM